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Abstract
Background: Mesenchymal stem cells derived from human umbilical cord tissue, termed UCX®, have the potential
to promote a full range of events leading to tissue regeneration and homeostasis. The main goal of this work was
to investigate UCX® action in experimentally induced hindlimb ischemia (HLI).
Methods: UCX®, obtained by using a proprietary technology developed by ECBio (Amadora, Portugal), were
delivered via intramuscular injection to C57BL/6 females after unilateral HLI induction. Perfusion recovery, capillary
and collateral density increase were evaluated by laser doppler, CD31 immunohistochemistry and diaphonisation,
respectively. The activation state of endothelial cells (ECs) was analysed after EC isolation by laser capture
microdissection microscopy followed by RNA extraction, cDNA synthesis and quantitative RT-PCR analysis. The
UCX®-conditioned medium was analysed on Gallios flow cytometer. The capacity of UCX® in promoting
tubulogenesis and EC migration was assessed by matrigel tubule formation and wound-healing assay, respectively.
Results: We demonstrated that UCX® enhance angiogenesis in vitro via a paracrine effect. Importantly, after HLI
induction, UCX® improve blood perfusion by stimulating angiogenesis and arteriogenesis. This is achieved through
a new mechanism in which durable and simultaneous upregulation of transforming growth factor β2, angiopoietin
2, fibroblast growth factor 2, and hepatocyte growth factor, in endothelial cells is induced by UCX®.
Conclusions: In conclusion, our data demonstrate that UCX® improve the angiogenic potency of endothelial cells
in the murine ischemic limb suggesting the potential of UCX® as a new therapeutic tool for critical limb ischemia.
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Background
Critical limb ischemia (CLI) is a severe form of periph-
eral artery disease (PAD) in which patients with occlu-
sive arterial disease of the legs experience chronic
ischemic rest pain, ulcer, or gangrene [1]. This syndrome
is associated with severe prognosis, with 1-year mortality
exceeding 25 % and about 30–50 % major limb amputa-
tion at 1 year from diagnosis [1]. The limitations of
surgical/endovascular revascularization, due the distribu-
tion and diffuseness of arterial occlusions, are well
recognized and amputation, despite its associated
morbidity and mortality rates, is often recommended
[2]. The goal of limb salvage has stimulated research into
alternative methods, including therapeutic angiogenesis
which can be achieved either by local administration of
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pro-angiogenic growth factors and gene- or cell-based
therapies [3].
Mesenchymal stem cells (MSCs) hold great promise as
a therapy for PAD, mainly due to their paracrine activity
and immunosuppressive capacity [4]. MSCs are known
to home specifically to hypoxic tissues following injury
[5] where they potentiate vascular growth through the
release of pro-angiogenic factors [6]. It was previously
reported that autologous, allogeneic and xenogeneic
MSC administration induced therapeutic angiogenesis in
animal models of hindlimb ischemia (HLI) [7]. In a
meta-analysis of cell therapy for PAD, it was found that
autologous bone marrow MSCs delivery led to improved
indices of ischemia and pain-free walking [8]. Although
first harvested from the bone marrow, MSCs have since
been identified in many other tissues, namely adipose
tissue [9] and umbilical cord tissue [10]. UCX® in
particular are MSCs obtained from the human umbilical
cord Wharton’s jelly that are isolated, expanded and cryo-
preserved according to a patented method (PCT/IB2008/
054067; WO 2009044379) and produced according to
advanced therapy medicinal product (ATMP) guide-
lines [11]. UCX® fulfil the MSC criteria as defined by
the International Society for Cellular Therapy (ISCT)
[12]. UCX® cells are advantageous in comparison to
other sources due to the absence of invasiveness in
their collection process, their faster self-renewal,
higher cell yield and being more potent modulators
of the immune system than bone marrow MSCs,
making them more attractive for allogeneic cellular
therapies.
Recently, it was demonstrated that UCX® paracrine
activity represses T cell activation and promotes the
expansion of regulatory T cells (Tregs) better than bone
marrow MSCs [13]. Furthermore, by using an acute
arthritis in vivo model it was found that UCX® can re-
duce paw edema more efficiently than bone marrow
MSCs. The use of a chronic arthritis model showed that
UCX® induce faster remission of local and systemic arth-
ritic manifestations [13]. The UCX® tissue regeneration
capacity suggested for rheumatoid arthritis was later cor-
roborated for myocardial infarction. By using a mouse
model of myocardial infarction, it was shown that UCX®
preserve cardiac function and attenuate adverse tissue
remodelling after intramyocardial transplantation [14].
Interestingly, it was demonstrated that this cardioprotec-
tive effect was exerted through paracrine mechanisms
involving angiogenesis promotion [14]. Furthermore, in
vitro studies, performed with conditioned medium (CM)
produced by UCX® grown in classical two-dimensional
monolayer cultures, have demonstrated the potential to
induce keratinocyte migration in the early stages of
wound healing [15]. Moreover, UCX® were able to attract
bone marrow MSCs in vivo with potential to promote
the formation of granulation tissue, contraction by myo-
fibroblasts, angiogenesis, vasculogenesis and epitheliza-
tion [15]. These results strongly suggest that UCX® have
the potential to promote a full range of events leading to
tissue regeneration and homeostasis. Interestingly, it
was shown recently that the later proliferative and re-
modelling stages of wound healing promoted by the
CM of the two-dimensional monolayer cultures were
improved by using three-dimensional culture-derived
CM [16]. An enhanced secretion of healing-inducing
paracrine factors by UCX® including the extracellular
cellular matrix metalloproteinase-2 (MMP-2) and
matrix metalloproteinase-9 (MMP-9), collagen I, fibro-
nectin, laminin, collagen IV and angiogenic factors
such as vascular endothelial growth factor A (VEGF-A),
granulocyte-colony stimulating factor (G-CSF), transform-
ing growth factor β1 (TGF-β1), fibroblast growth factor 2
(FGF-2), hepatocyte growth factor (HGF) and interleukin
6 (IL-6) was observed in the CM of three-dimensional cul-
tures based on self-assembled spheroids [16].
In this work, our data corroborate that UCX® enhance
angiogenesis in vitro and in vivo, by modulating endo-
thelial cells. In vitro, we found that UCX® promote
tubule formation and endothelial cell migration. Import-
antly, our results have demonstrated that UCX® in the
setting of experimentally induced unilateral hindlimb
ischemia (HLI) stimulate angiogenesis and collateral ves-
sel development and thereby improve blood perfusion in
the ischemic limb demonstrating the potential of UCX®
as new therapeutic tool for CLI. Furthermore, and to the
best of our knowledge, this is the first study in an ex-
perimental model of hindlimb ischemia showing that, in
vivo and in a sustained way human MSCs upregulate the
endothelial gene expression of several pro-angiogenic
players (such as transforming growth factor β2 (Tgfβ2),
angiopoietin 2 (Ang-2), Fgf-2, Hgf ), shedding light on the
potential mechanisms of action of this particular ATMP.
Methods
Ethics and regulations
All animal procedures were performed according to Direct-
ive 2010/63/EU. The procedures were approved by the in-
stitutional Animal Welfare Body and licensed by DGAV,
the Portuguese competent authority for animal protection
(license number 023861/2013).
Cell culture
UCX® were cultured in static monolayers in α-MEM
with 1 g/L glucose and 2 mM glutamine (Sigma-Aldrich,
St. Louis, MO, USA), hereafter designated basal medium
(BM), supplemented with 20 % foetal bovine serum
(FBS; Gibco®, Madrid, Spain), in a humidified incubator
at 37 °C and 7 % CO2.
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Human umbilical vein endothelial cells (HUVECs)
(Sciencell, Carlsbad, CA, USA) were cultured in M199
media (Sigma-Aldrich, St. Louis, MO, USA), hereafter
designated endothelial basal medium (EBM) supple-
mented with 10 % FBS (Gibco™, Thermo Fisher Scien-
tific, Waltham, MA, USA), 50 μg/ml endothelial cell
growth supplement (ECGS) (Sigma-Aldrich), 100 μg/ml
heparin (Sigma-Aldrich) and 1 % penicillin-streptomycin
(10,000 U/mL, Sigma-Aldrich), hereafter designated
endothelial growth medium (EGM). Cells were grown in
flasks coated with 0.2 % gelatin (Sigma-Aldrich) until
70 % confluence and used up to passage 6.
Preparation of conditioned media
UCX® were seeded in BM supplemented with 5 % FBS
and grown until 90 % confluence. After washing cells
with phosphate-buffered saline (PBS), BM (without
serum) was added for 24 hours. Thereafter, BM was re-
placed and conditioned for 48 hours at 37 °C and 7 %
CO2 after which it was collected, centrifuged at 300 g for
10 minutes to remove cell debris, filtered (0.22 μm pore
size, Merck Millipore, Billerica, MA, USA), and concen-
trated using 5 kDa cut-off spin concentrators (Agilent
Technologies, Santa Clara, CA, USA) as per manufac-
turer’s recommendations. Control conditioned medium
samples underwent the same procedure as described
above, but in the absence of cells.
Quantification of secreted factors
The quantification of HGF, VEGF-A, TGF-β1, IL-8,
platelet-derived growth factor-AA (PDGF-AA) and
FGF-2 in the conditioned medium was performed using
a commercially available kit (FlowCytomix™; eBioscience,
San Diego, CA, USA) according to the manufacturer’s
instructions. Samples were acquired on a Gallios flow
cytometer (Beckman Coulter, Brea, CA, USA) and the
results obtained using FlowCytomix Pro 3.0 Software
(eBioscience).
Tubule formation assay
The tubule formation assay was performed using the thick
gel method of preparation. Briefly, after thawing over-
night, the matrigel (Corning, Corning, NY, USA) was
plated into a pre-cooled 48-well plate (Nunc™, Thermo
Fisher Scientific) (180 μl per well) using a chilled pipet tip.
After polymerization of matrigel at 37 °C, 5 % CO2, for
45 minutes, HUVECs were inoculated at a density of
4.5 × 104 cells/cm2 on top of the matrigel in 350 μl of
EBM. Cells were then incubated for 1 hour at 37 °C, 5 %
CO2. 1 × 10
6 UCX® were resuspended in 350 μl BM and
loaded on a 1-μm insert (Brand, Wertheim, Germany) and
carefully placed in a 48-well plate and incubated for
16 hours at 37 °C, 5 % CO2. Controls with no UCX®
included HUVECs in (i) EBM, (ii) EGM and (iii) EBM
supplemented with FGF-2 (50 ng/ml). After incubation,
inserts were removed and all wells were photographed
(×10 amplification) using a Nikon Eclipse Ti-U inverted
microscope with a conjugated Nikon DS-Qi1Mc camera
(Nikon, Tokyo, Japan). Tubule formation was quantified
on four random fields per replicate, using the Angiogen-
esis analyser from Image J.
Wound-healing assay
HUVECs were plated to confluence in a 24-well plate
(previously coated with gelatine 0.2 %) with EBM
supplemented with 5 % FBS. After culturing overnight,
wounds were created in the monolayer by scrapping the
plate with a sterile pipette tip. After that, 1 × 106 UCX®,
resuspended in EBM supplemented with 5 % FBS and
loaded on a 1-μm insert (Brand, Wertheim, Germany),
were carefully placed in a 24-well plate and incubated
for 9 hours at 37 °C, 5 % CO2. In controls, the same pro-
cedure was performed in the absence of UCX®. Photo-
graphs were taken in Primovert (Carl Zeiss Microscopy,
Jena, Germany) on a × 4 magnification and three inde-
pendent wound areas were measured with ImageJ imme-
diately after wounding and 9 hours later.
Mice
Twenty-two-week-old C57BL/6 female mice, purchased
from Charles River Laboratories, Barcelona, Spain, were
used in all experiments. The animals were anaesthetised
with a ketamine-medetomidine cocktail (75 mg/kg BW
and 1 mg/kg BW, respectively) intraperitoneally for the
surgical procedure as well as for the other analysis
procedures. The anaesthesia was partially reverted with
atipamezole (5 mg/kg BW). Postoperatively, analgesia
was performed (buprenorphine 100 μl/15–30 g BW
every 8–12 h) and the animals were closely monitored.
HLI model
A surgical procedure was performed to induce unilateral
HLI in the mice. Briefly, an incision in the skin overlying
the thigh of the right hindlimb of each mouse was made
and the distal external iliac artery and the femoral artery
and veins were ligated and excised. The vein was ligated
both to increase the severity of the ischemia as well as
to increase the technical reproducibility of the model, as
isolation of the femoral artery alone often results in tear-
ing of the vein resulting in haemorrhage.
UCX® administration
A dose of 2 × 105 UCX® was injected intramuscularly,
5 hours post-ischemia induction on the gastrocnemius
muscle (right hindlimb) in a volume of 50 μl per animal,
divided into two injections of 25 μl. As a control, UCX®
vehicle (PBS) was administered at the same conditions.
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Laser doppler perfusion imaging
The laser doppler perfusion imager (MoorLDI V6.0,
Moor Instruments Ltd, Axminster, UK) was used to as-
sess limb perfusion. Hair was removed 1 day before laser
doppler analysis using an electrical shaver followed by
depilatory cream. Blood flow was measured both in the
ischemic leg and the contralateral one, before HLI in-
duction (PRE-HLI), immediately post-HLI (POST-HLI),
and at day 7, 14 and 21 post-HLI (d7 POST-HLI, d14
POST-HLI and d21 POST-HLI, respectively). Colour-
coded images of tissue perfusion were recorded and
poor or no perfusion was displayed as dark blue, and the
highest perfusion level was displayed as red. Mean flux
values were calculated using the MoorLDI V6.0 image
processing software. To account for variables such as
temperature and ambient light, blood perfusion is
expressed as the ratio of ischemic to non-ischemic limb.
The mice were placed on a 37 °C heating pad to reduce
heat loss during measurements.
Immunohistochemistry and capillary density analysis
Mice were sacrificed at day 90 post-HLI (to assure capil-
lary stabilization after the ischemic injury). The gastro-
cnemius muscles of both legs were harvested, placed in
transverse orientation on a small cork disc with the help
of 10 % tragacanth, snap frozen in liquid nitrogen-
cooled isopentane and stored at -80 °C until sectioned.
Seven-micrometer sections were labeled with CD31
monoclonal antibody (Pharmingen, San Diego, CA,
USA). After fixation in acetone for 10 minutes, hydrogen
peroxidase (0.3 % diluted in methanol) was added for
30 minutes, at room temperature (RT) and followed by
two washes in PBS for a total of 10 minutes. Blocking
solution (5 % rabbit serum in PBS) was applied for
30 minutes, at RT, and the slides were then incubated
for 1 hour at RT with rat monoclonal antibody against
mouse CD31 at 1:500, diluted in 1 % bovine serum albu-
min (BSA) in PBS. After three washes in PBS for a total
of 30 minutes, a secondary biotinylated rabbit anti-rat
IgG antibody was added at 1:200 in 1 % BSA in PBS and
5 % rabbit serum for 30 minutes, at RT. Washes were
performed as before and labeled avidin-conjugated per-
oxidase complex (Vectastain ABC kit; Vector Laborator-
ies, Burlingame, CA, USA) was used for color
development according to the manufacturer’s recom-
mendations for 30 minutes, at RT. After rinsing in PBS
(three times for 5 minutes), DAB peroxidase substrate
kit (Dako, Glostrup, Denmark) was added for 5 minutes
to localize the immune complexes. The sections were
counterstained with haematoxylin (Merck, Kenilworth,
NJ, USA) for 10 seconds and mounted with entelan
(Merck). Omission of the first antibody was used as a
negative control. Analysis of tissue samples was
conducted using a Leica DM2500 upright brightfield
microscope (Leica Microsystems, Wetzlar, Germany).
Capillary densities, i.e. number of capillaries per number
of myocytes, were measured in two different sections of
four distinct anatomic areas of each specimen using the
ImageJ software.
Contrast agent perfusion and diaphonisation
Ninety days post-ischemia induction (to assure vascular
stabilization after the ischemic injury), mice were deeply
anaesthetised and the torso and limbs were shaved. A
medial thoracotomy was performed to expose the heart
and a needle (26 gauge), attached to an automatic in-
jector, was introduced in the left ventricle. An incision
was performed in the right atrium to allow venous
drainage. Mice were primarily perfused with heparinized
serum (3000 IU/L) until the blood was completely re-
moved from circulation. A vasodilatation mixture of ad-
enosine (1 mg/L) and papaverine (4 mg/L) was
subsequently administered, right before the contrast
agent, for 2 minutes. The contrast used was a mixture of
barium sulfate (50 %) and gelatin (5 %). This solution
was kept warm until the injection time to avoid thicken-
ing. Contrast agent was perfused manually until the feet
blanched. Right after the injection the mice were trans-
ferred to a cold chamber, so that the contrast agent
became solidified. All the solutions were injected with a
perfusion rate of 0.7 mL/minute. Then, the skin of each
mouse was removed from the lower body and diaphoni-
sation was performed by using a modified version of the
Spalteholz technique. Briefly, the mice were fixated,
decalcified, whitened, washed, dehydrated by freeze
substitution and placed into a vacuum pump with
Spalteholz solution (benzyl benzoate and methyl salicyl-
ate) until transparency was acquired.
Collateral vessels quantification
Mice were kept in Spalteholz solution during image
acquisition, in order to achieve a homogenous density
between the tissues and the media, with minimal absorp-
tion or reflection of light. Mice entire limbs were photo-
graphed in a magnifier with a light source. After
acquisition, images were aligned and stitched together
using Adobe Photoshop CS6®, and entire limb photo-
graphs were obtained. In order to exclude the femoral
artery and all venous structures from this quantification,
only the collateral vessels were manually segmented by
highlighting them using Adobe Photoshop CS6®. We
considered as collateral vessels all the vessels with a diam-
eter between 20 and 300 μm. For every mouse, an ana-
tomically determinable region comprising the ligation site
was selected and defined as a region of interest (ROI).
Collateral vessels density (CVD) was quantified in equiva-
lent ROIs corresponding to 20 % of the total limb area.
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The CVD was calculated as the ratio between the vascular
and the ROI areas.
To exclude variations in the anatomy, perfusion and
diaphonization procedures, the CVD value of the non-
ischemic limb obtained for each mouse was assumed to
correspond to 100 %. According to this assumption, the
CVD percentage in the ischemic limb was calculated
relatively to the non-ischemic one. The percentage of
CVD increase was determined as the difference between
the CVD percentage among the ischemic and non-
ischemic limbs. Means of CVD percentages and stand-
ard deviations were calculated for each experimental
group. All density measurements were performed using
ImageJ software.
Laser capture microdissection of capillaries
Mice were sacrificed at day 70 post-HLI. Twelve-
micrometer sections of the gastrocnemius muscles were
labeled with CD31 monoclonal antibody (Pharmingen).
The sections were stored at –80 °C until microdissec-
tion. The immunohistochemistry protocol described
above was modified to improve RNA preservation by
using high salt buffer, 2 M NaCl in PBS 1× (at 4 °C) in
all incubation and washing steps [17]. Briefly, slides were
placed in acetone, for 5 minutes, air-dried, rehydrated
with 2 M NaCl/PBS (4 °C) and incubated, overnight, at
4 °C with rat monoclonal antibody against mouse CD31,
at 1:500, in 2 M NaCl/PBS. After two washes in 2 M
NaCl/PBS for a total of 6 minutes, a secondary biotinyl-
ated rabbit anti-rat IgG antibody was added at 1:200 in
2 M NaCl/PBS and 5 % rabbit serum for 30 minutes, at
4 °C. Washes were performed as before and labeled
avidin-conjugated peroxidase complex (Vectastain ABC
kit; Vector Laboratories) was used for color development
according to the manufacturer’s recommendations for
30 minutes, at 4 °C. After rinsing, DAB peroxidase
substrate kit (Vector Laboratories) was added for 5 mi-
nutes to localize the immune complexes. Sections were
dehydrated in ice-cold 90 % ethanol followed by 100 %
ethanol and allowed to dry. Ten thousand capillaries
were microdissected using a Zeiss PALM MicroBeam
Laser Microdissection System (Carl Zeiss Microscopy)
equipped with a pulsed solid-state 355 nm laser.
Dissected capillaries were catapulted into a microfuge
tube adhesive cap.
RNA extraction, cDNA synthesis, pre-amplification and RT-PCR
Total RNA from the microdissected capillaries was
isolated using an RNeasy Micro Kit (QIAGEN, Hilden,
Germany), including DNase treatment to remove
potential genomic DNA contamination. For synthesis
and preamplification of cDNA, RT2 PreAMP cDNA
Synthesis Kit (QIAGEN) was used with two rounds of
pre-amplification using the following primers: Fgf-2_F
(5′- ACTCCAGTTGGTATGTGGCACTGA-3′); Fgf-2_
R (5′-AACAGTATGGCCTTCTGTCCAGGT-3′); Tgfb-
2_F (5′-GCTTTGGATGCGGCCTATTGCTTT-3′); Tgf
b-2_R (5′-CTCCAGCACAGAAGTTGGCATTGT-3′);
Ang-2_F (5′-ATCCAACACCGAGAAGATGGCAGT-3′);
Ang-2_R (5′-AACTCATTGCCCAGCCAGTACTCT-
3′); Hgf_F (5′-GCATTCAAGGCCAAGGAGAAGGT
T-3′); Hgf_R (5′-TCATGCTTGTGAGGGTACTGCG
AA-3′); 18s_F (5′-GCCCTATCAACTTTCGATGGTA
GT-3′); 18s_R (5′- CCGGAATCGAACCCTGATT-3′).
RT-PCR was performed according to the manufac-
turer’s protocol using Power SYBR® Green (Invitro-
gen, Carlsbad, CA, USA) and an Applied Biosystems
(Waltham, MA, USA) 7500 Fast Real-Time PCR for
the same targets described above. The housekeeping
gene used to normalize was 18S. The RT-PCR pro-
gram consisted of an initial denaturation step, at 95 °
C, for 10 minutes followed by 50 cycles, at 95 °C, for
15 seconds and at 60 °C, for 1 minute. The relative
quantification was performed according to the com-
parative method (2-ΔΔCt; Applied Biosystems User
Bulletin no. 2P/N 4303859), with the non-ischemic
muscle as an internal calibrator. The formula used is
2-ΔΔCt =2-[ΔCt (sample) - ΔCt (calibrator)], where ΔCt
(sample) = Ct (sample) –Ct (reference gene). For the
internal calibrator ΔΔCt = 0 and 20 = 1. For the
remaining samples the value of 2-ΔΔCt indicates the
fold change in gene expression relative to the calibra-
tor. The ΔCt value for each sample is the average of
triplicates.
Statistical analysis
For the wound-healing assay, the values assume normal
distribution and unequal variances and therefore an inde-
pendent two-tailed t test was performed. For doppler ana-
lysis, an independent two-tailed t test was also performed
at days 7, 14 and 21. The values assume normal distribu-
tion. Only at day 7, we cannot assume equal variances.
For capillary and collateral analysis, the values also assume
normal distribution and equal variances and therefore an
independent two-tailed t test was also performed. For the
master junctions and segment length, one-way independ-
ent analysis of variance (ANOVA) was developed as data
followed a normal distribution, though equality of
variances could not be assumed for the first. Therefore, a
Games-Howell corrected post hoc test was used to iden-
tify differences between groups. For the meshes area, as
normality could not be assumed and so a Kruskal-Wallis
non-parametric test was developed followed by its paired
analysis to identify differences between groups. The effect
size and power was determined by using the G-Power
software in all type of analyses. p < 0.05 was interpreted to
denote statistical significance.
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Results
UCX® promote tubulogenesis and endothelial cell
migration
We first evaluated the effect of UCX® on the capillary
structure formation. A matrigel tubule formation assay
was used as an in vitro model. HUVECs were seeded
onto matrigel in endothelial basal medium (EBM) and
co-cultured with UCX®. As a control HUVECs were
seeded in EBM, where we do not expect to visualize
capillary-like structures formed by HUVECS. For that
reason, two positive controls were added and HUVECs
were seeded both in endothelial growth medium (EGM)
that contains several pro-angiogenic factors such as
VEGF and FGF-2 and in EBM supplemented with FGF-2
(EBM-FGF-2). As shown in Fig. 1a and quantified in
Fig. 1b, UCX® induce tubule formation by HUVECs and
these structures consistently showed a significant in-
crease in the number of master junctions, total mesh
area and total segment length when compared to those
from HUVECs cultured in EBM or EGM. With the ex-
ception of the total mesh area, all the measured parame-
ters were also significantly different between HUVECs
cultured with UCX® in EBM and HUVECs cultured in
EBM supplemented with FGF-2. Next, we assessed the
migratory capacity of HUVECs seeded in EBM supple-
mented with 5 % of serum co-cultured with UCX® with-
out cell to cell contact. With this objective, a wound-
healing assay was performed and as a control HUVECs
were seeded in the same culture conditions but in the
absence of UCX®. As shown in Fig. 2a and b, the wound
area decreased more rapidly in the presence of UCX®
than in the control condition, suggesting that UCX®
promote the migration of HUVECs via a paracrine
secretion. Taken together, these results clearly show that,
in vitro, UCX® induce angiogenic processes in endothe-
lial cells.
A
B
C
Fig. 1 UCX® promote tubulogenesis. Matrigel assay was performed by seeding human umbilical vein endothelial cells (HUVECs) in endothelial basal
medium (EBM), endothelial growth medium (EGM), EBM supplemented with fibroblast growth factor 2 (FGF-2) (EBM + FGF-2) or EBM co-cultured with
UCX®. (a) Representative images from the different experimental conditions are shown. (b) Quantitative evaluation demonstrated significantly
enhanced master junctions, total mesh area and total segment length in capillary-like structures formed in HUVECs co-cultured with UCX® when
compared to the other experimental conditions. For master junctions, following Games-Howell post hoc test the mean differences between UCX® and
the other experimental conditions were: EBM (mean dif. =24.27; p = 0.01); EGM (mean dif. = 19.67; p = 0.03) and EBM + FGF-2 (mean dif. = 13.8;
p = 0.034). The effect size to basal was 2.08 and power 0.98. For the meshes area, following pairwise comparisons, the equivalent to a post hoc
Kruskal-Wallis test, significant differences between UCX® and EBM or UCX® and EGM were observed with KW = 22.66, p < 0.01 or KW= 18.77, p = 0.01,
respectively. For segment length, following Games-Howell post hoc test, UCX® show significant difference when compared to the other groups: EBM
(mean dif. = 4920; p < 0.001); EGM (mean dif. = 3346; p = 0.01) and EBM + FGF-2 (mean dif. = 2223; p = 0.016). Effect size to basal was 3.85 and power
1. Scale bar, 500 μm
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UCX® secrete pro-angiogenic factors
Since it was already demonstrated that the beneficial
effects promoted by UCX® result from a paracrine secre-
tion, we decided to evaluate the secretion of six repre-
sentative trophic factors critical for angiogenesis in the
conditioned medium of an UCX® monolayer seeded in
basal medium (BM) for 48 hours. As a control, the same
trophic factors were measured in BM that had not been
in contact with cells. The expression of HGF, VEGF-A,
TGF-β1, interleukin 8 (IL-8), platelet-derived growth
factor-AA (PDGF-AA) and FGF-2 were analysed. Our
results show a significant increase of HGF, TGF-β1, IL-8
and PDGF-AA in the conditioned medium of UCX®
when compared to the control (Table 1), demonstrating
that UCX® secrete pro-angiogenic factors to the extracel-
lular medium.
UCX® increase perfusion recovery after HLI
In order to evaluate the therapeutic potential of UCX® in
a HLI mouse model, the perfusion recovery was assessed
over time after ischemia induction and UCX® adminis-
tration. Five hours after surgical induction of unilateral
HLI, UCX® or their vehicle (as a control) were adminis-
tered in the ischemic muscle and perfusion was mea-
sured over time. As shown in Fig. 3a and quantified in
Fig. 3b, a dramatic reduction in blood flow was observed
in the ischemic limb immediately after surgery, in com-
parison to the contralateral limb, followed by a gradual
normalization of ischemic blood flow over time. Import-
antly, UCX® markedly improved blood flow recovery at
7, 14 or 21 days post-HLI, comparing with control mice,
demonstrating that UCX® administration contributes to-
ward the functional recovery of ischemic tissues.
A
B
Fig. 2 UCX® stimulate endothelial cell migration. Human umbilical vein endothelial cells (HUVECs) were seeded to confluence in endothelial basal
medium (EBM) supplemented with 5 % FBS and cultured for 16 hours after wounding. Immediately after wound, HUVECs were co-cultured with
UCX® or not (control) for 9 hours. (a) Representative images are shown. The left and right panels concern HUVEC monolayer immediately after or
9 hours post-wounding, respectively. (b) The wound area was measured immediately after and 9 hours post-wounding by using ImageJ software
(three independent measurements were performed for each experimental group; t (2.03) = 4.66; *p < 0.05); effect size was 3.82 and power 0.93)
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UCX® increase capillary and collateral vessel density after
HLI
As blood flow recovery depends on both angiogenesis
and arteriogenesis we examined whether UCX® would
affect capillary and collateral vessel densities in hindlimb
muscles. Five hours after surgical induction of unilateral
HLI, UCX® or their vehicle (as a control) were adminis-
tered in the ischemic muscle and mice were sacrificed
90 days post-HLI induction. Capillary density was
assessed through quantification of CD31-positive capil-
laries on histological sections of gastrocnemius muscle.
As expected, the capillary density was greater in the
ischemic versus the non-ischemic hindlimb in both ex-
perimental groups (Fig. 4b). Notably, the level of capil-
lary density in the ischemic hindlimb treated with UCX®
was significantly higher than the one observed in the
control ischemic hindlimb, as shown in Fig. 4a and
quantified in Fig. 4b. In order to evaluate the collateral
vessel density (CVD), mice were diaphonised and an
equivalent region of interest (ROI), corresponding to
20 % of the limb area, was selected for CVD quantifica-
tion (Fig. 4c). A significantly higher CVD increase was
observed in UCX®-treated mice when compared to the
control (Fig. 4d). Taken together, our results show that
A
B
Fig. 3 UCX® increase perfusion recovery. UCX® or their vehicle (as a control) were administered in the ischemic gastrocnemius muscle 5 hours after HLI
induction. (a) Representative laser doppler flow images before (PRE-HLI), immediately after (d0 POST-HLI) and at 7, 14 and 21 days post-HLI induction
(d7 POST-HLI, d14 POST-HLI, d21 POST-HLI). (b) Quantitative evaluation of blood flow expressed as a ratio of ISC to NISC limb demonstrated significantly
enhanced limb blood perfusion in UCX®-treated mice at 7, 14 and 21 days post-HLI. (n = 16 for each experimental group; D7: t (22.69) = 4.26; ***p < 0.001;
effect size was 1.51 and power 0.98; D14: t (30) = 4.7; ***p < 0.001; effect size was 1.66 and power 0.99; D21: t (30) = 7.22; ***p < 0.001; effect size was 2.56
and power 0.99). HLI hindlimb ischemia, ISC ischemic, NISC non-ischemic
Table 1 Pro-angiogenic factors present in the conditioned medium from UCX® or basal medium
UCX® CM (pg/ml)
Mean±SEM
Basal CM (pg/ml)
Mean±SEM
t-test
HGF 2,64 ± 0,718 0,001 ± 0 0,0144
VEGF-A 2,025 ± 1,043 0,001 ± 0 0,1099
TGF-β1 0,983 ± 0,122 0,001 ± 0 0,0005
IL-8 0,765 ± 0,069 0,001 ± 0 0,0001
PDGF-AA 0,123 ± 0,045 0,001 ± 0 0,0412
FGF-2 0,0317 ± 0,009 0,02 ± 0 0,2874
CM conditioned medium
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UCX® significantly augment capillary density and CVD
increase after ischemic injury.
UCX® upregulate the endothelial Tgf-β2, Ang-2, Fgf-2 and
Hgf expression in response to HLI
To elucidate the mechanism of action of UCX® in our
HLI model we investigated if UCX® could change the
endothelial gene expression. For this purpose, 5 hours
after surgical induction of unilateral HLI, UCX® or their
vehicle (as a control) were administered in the ischemic
muscle and mice were sacrificed at day 70 post-HLI in-
duction. The gastrocnemius muscle sections were
stained for CD31 and visualized using a Laser Capture
Microdissection microscope. CD31-positive cells were
dissected, isolated and analysed by quantitative RT-PCR
for the expression of several pro-angiogenic factors. Our
results show that transcripts for Tgf-β2, Ang-2, Fgf-2 and
Hgf were clearly upregulated in endothelial cells isolated
from muscle of the ischemic limb, comparing with those
found in endothelial cells from the contralateral limb.
This is observed exclusively in mice treated with UCX®.
Control mice show the opposite trend, downregulating
the expression of the angiogenic genes in endothelium
from the ischemic limb, when compared with the
contralateral limb (Fig. 5). These results suggest that the
mechanism of action of UCX® in the HLI mouse model
involves the upregulation of several angiogenic genes in
the endothelial cells present in the ischemic muscle.
Discussion
CLI is a manifestation of peripheral arterial disease that
describes patients with chronic ischemic rest pain, ulcers
or gangrene [1]. Available therapies are limited and pa-
tients may require amputation. The goal of limb salvage
has stimulated research into alternative methods, includ-
ing therapeutic angiogenesis. Stem cell therapy holds
great potential for therapeutic angiogenesis, but its clin-
ical translation has been slow due to (i) lengthy proce-
dures performed ex vivo in which stem cells are
manipulated and often lose viability, differentiate or
A B
C D
Fig. 4 UCX® increase capillary and collateral densities. UCX® or their vehicle (as a control) were administered in the ischemic gastrocnemius muscle
5 hours after HLI induction. (a) Representative sections from control and UCX®-treated ischemic gastrocnemius muscles at 90 days post-HLI. Capillaries
and myocytes were identified by CD31 immunohistochemistry and haematoxylin, respectively. Scale bar, 125 μm. (b) Quantitative analysis, at 90 days
post-HLI, revealed increased capillary density (capillaries/myocyte) in UCX®-treated ischemic gastrocnemius muscles compared to control ischemic
ones. (n = 3 and n = 7 for control and UCX®, respectively; t (8) = 4.44; **p = 0.0057; effect size was 3.064 and power 0.97). (c) Illustrative images of se-
lected regions of interest (ROI) for control and UCX®-treated mice. ISC and NISC limbs are shown. Scale bar, 1 mm (d) Data are represented as the per-
centage of collateral vessel density (CVD) increase of the ISC limb relatively to the NISC one. At 90 days post-HLI, UCX®-treated mice presented
significantly higher CVD increase (%) when compared to control mice (n = 5 for each experimental group; t (8) = 7.63; ***P = 0.000062; effect size was
4.82 and power 0.99). ISC ischemic, NISC non-ischemic
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change their characteristics, and (ii) the high costs in-
volved. In addition, the clinical use of bone marrow
MSCs has demonstrated some caveats, mainly due to
low yields which further decrease with donor’s age and
medical condition, leading to variable and/or limited cell
doses.
Among the other possible sources for MSCs, there is
the umbilical cord tissue [10], from which UCX® are de-
rived. UCX® have already demonstrated the potential to
lead to tissue regeneration and homeostasis, promoting
faster remission of local and systemic manifestations of
inflammatory arthritis [13]; preserving cardiac function
after intramyocardial transplantation in a myocardial in-
farction murine model [14]; and accelerating wound
healing [15]. Those studies strongly suggest that UCX®
act in different cell types through paracrine mechanisms.
In addition, it was found that conditioned medium of
UCX® cultures induces fibroblast and keratinocyte mi-
gration and UCX® are chemotactic to CD34-/CD45-
bone marrow MSCs [15]. Further, it was also shown that
in vitro UCX®-conditioned medium induces angiogenesis
by promoting the formation of capillary-like structures
by HUVECs [13]. Herein, we corroborated those find-
ings showing that UCX® promotes tubulogenesis and
endothelial cell migration. We observed that UCX® when
co-cultured with HUVECs induce tubule formation by
HUVECs to a higher extent than the known pro-
angiogenic factor FGF-2, and also promote migration.
As already demonstrated for other cell types, our data
strongly suggest that UCX® act in endothelial cells
through paracrine mechanisms since a significant
increase of pro-angiogenic factors such as HGF, TGF-β1,
IL-8 and PDGF-AA was observed in the conditioned
medium of UCX® when compared to the control.
In order to investigate if UCX® could promote thera-
peutic angiogenesis in a HLI context, we developed an
experimental model of unilateral HLI and two important
parameters were assessed: angiogenesis and arteriogen-
esis. Our data indicate that UCX® administration signifi-
cantly induces blood perfusion recovery in the limb after
HLI induction. Accordingly, a significantly higher capil-
lary density and CVD increase was found in the ische-
mic muscles after UCX® treatment. These evaluations
were performed at day 90 post-HLI suggesting that the
effect induced by UCX® in angiogenesis and arteriogen-
esis is maintained over time. Besides, the non-ischemic
muscles are unaffected by UCX® since capillary density
and CVD are similar in non-ischemic muscles both from
UCX®-treated and control mice, indicating that UCX®
might have a local action. These data suggest that UCX®
could secrete cytokines/chemokines and paracrinally
interfere with the ischemic microenvironment contribut-
ing to a therapeutic angiogenesis. More importantly, a
new mechanism of action of UCX® is demonstrated for
the first time: UCX® modulate the expression of pro-
angiogenic players in endothelial cells. We found that
70 days post-HLI and UCX® treatment, endothelial cells
isolated from UCX®-treated microenvironment present
an upregulation in their expression levels for Tgfβ2,
Ang-2, Fgf-2 and Hgf when isolated from the ischemic
gastrocnemius muscle in comparison with the contralat-
eral one. This effect is UCX®-specific as the opposite is
Fig. 5 UCX® upregulate the expression of Tgf-β2, Ang-2, Fgf-2 and Hgf in endothelial cells isolated from ischemic gastrocnemius muscles. UCX® or their
vehicle (as a control) were administered in the ischemic gastrocnemius muscle 5 hours after HLI induction. At 70 days post-HLI, the expression of
pro-angiogenic factors and their receptors was evaluated by qRT‐PCR exclusively on endothelial cells isolated from gastrocnemius muscles. Each bar
represents the relative gene expression in one animal. White and grey bars represent control and UCX®-treated mice, respectively. Values were
normalized to 18S to obtain relative expression levels. Results expressed as log2 fold changes between ISC and NISC samples demonstrated
relative abundance of the transcripts in UCX®-treated mice; in contrast, a downregulation is observed in control mice. ISC ischemic,
NISC non-ischemic
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verified in control mice. According to these findings, we
show that UCX® simultaneously upregulate the expres-
sion of several angiogenic factors in endothelial cells and
by this mechanism we may hypothesize that UCX® im-
prove their endogenous angiogenic potency in an ische-
mic context. This could be very relevant when compared
to other strategies where only a single angiogenic factor
is administered, especially if we understand angiogenesis
as a complex process that involves multiple cytokines. It
is also very interesting to note that the same factors
modulated by UCX® have been extensively studied in
therapeutic angiogenesis. Specifically, in gene and pro-
tein therapy, FGF-2 was used in a rabbit model of HLI
[18], where it was shown to promote the development of
collateral vessels. The efficacy of FGF-2 was also evalu-
ated in clinical trials such as FIRST (FGF Initiating Re-
vascularization Trial) [19] and TRAFFIC (Therapeutic
Angiogenesis with Recombinant FGF-2 for Intermittent
Claudication) [20]; however, it did not show a sustained
success [21]. Concerning HGF, it was also used in
clinical trials through gene transfer to treat CLI, where
its safety was shown [22]. More rigorous controlled trials
(randomised and placebo-controlled studies with larger
numbers of patients) are currently ongoing. Given the
fact that CLI is a common complication of diabetes
mellitus, future studies should assess the UCX® efficacy
in a diabetic experimental model since diabetes may
adversely affect EPC function and thus limit therapeutic
efficacy. Recent data have further shown that the
secreted proangiogenic protein osteopontin (OPN),
significantly downregulated in diabetic EPCs, could
increase the secretion of angiogenic proteins from EPCs
increasing their therapeutic efficacy [23]. Importantly,
these findings show that the function of EPCs could be
modulated and raise interesting questions for future
investigation, such as, (a) which molecules could eventu-
ally improve the therapeutic efficacy of UCX® in an
ischemic microenvironment; (b) could different ischemic
microenvironments modulate differently the function
of UCX®; if so, by which mechanisms; and (c) should
UCX® be modulated by the administration of selected
molecules according to the pathologies associated
with CLI.
Conclusions
In conclusion, here we propose a model of enhanced
and sustained angiogenesis induction by using UCX® as
a promising therapeutic approach for CLI. UCX® signifi-
cantly induce blood perfusion, capillary density and
collateral development. This could be at least in part
achieved by a new mechanism since we show that UCX®
upregulate the simultaneous expression of several pro-
angiogenic factors in endothelial cells that could
improve their angiogenic potency.
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